Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.

Autor: Cuyàs E; Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain.; Girona Biomedical Research Institute (IDIBGI), Girona, Spain., Buxó M; Girona Biomedical Research Institute (IDIBGI), Girona, Spain., Ferri Iglesias MJ; Laboratori Clínic Territorial, Parque Hospitalario Martí i Julià, Salt, Spain., Verdura S; Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain.; Girona Biomedical Research Institute (IDIBGI), Girona, Spain., Pernas S; Breast Unit, Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Dorca J; Medical Oncology, Catalan Institute of Oncology, Girona, Spain., Álvarez I; Medical Oncology Service, Hospital Universitario Donostia, Donostia-San Sebastián, Spain.; Biodonostia Health Research Institute, Donostia-San Sebastián, Spain., Martínez S; Medical Oncology Department, Hospital de Mataró, Mataró, Barcelona, Spain., Pérez-Garcia JM; Hospital Quirón, IOB Institute of Oncology, Barcelona, Spain., Batista-López N; Medical Oncology Service, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain., Rodríguez-Sánchez CA; Medical Oncology Service, Hospital Universitario de Salamanca, Salamanca, Spain.; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain., Amillano K; Medical Oncology, Hospital Universitari Sant Joan, Reus, Spain., Domínguez S; Medical Oncology Service, Hospital Universitario Araba, Vitoria-Gasteiz, Spain., Luque M; Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain., Morilla I; Breast Unit, Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Stradella A; Breast Unit, Department of Medical Oncology, Catalan Institute of Oncology-Hospital Universitari de Bellvitge-Bellvitge Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Viñas G; Medical Oncology, Catalan Institute of Oncology, Girona, Spain., Cortés J; Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid, Spain., Joven J; Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, IISPV, Rovira i Virgili University, Reus, Spain., Brunet J; Medical Oncology, Catalan Institute of Oncology, Girona, Spain.; Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.; Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Girona Biomedical Research Institute (IDIBGI), Girona, Spain., López-Bonet E; Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona, Spain., Garcia M; Clinical Research Unit, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Saidani S; Unit of Clinical Research, Catalan Institute of Oncology, Girona, Spain., Queralt Moles X; Laboratori Clínic Territorial, Parque Hospitalario Martí i Julià, Salt, Spain., Martin-Castillo B; Unit of Clinical Research, Catalan Institute of Oncology, Girona, Spain., Menendez JA; Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Spain.; Girona Biomedical Research Institute (IDIBGI), Girona, Spain.

Publikováno v: Frontiers in oncology [Front Oncol] 2019 Mar 28; Vol. 9, pp. 193. Date of Electronic Publication: 2019 Mar 28 (Print Publication: 2019).